Navigation Links
DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
Date:9/24/2008

tion, a procedure commonly employed by retinal specialists.

Currently, nearly 24 million people, or 8 percent of the population, in the U.S. have diabetes. Over time, all diabetics are at risk of developing some form of diabetic retinopathy, an ophthalmic condition of diabetes. In the U.S., diabetic retinopathy causes approximately 12,000 to 24,000 new cases of blindness each year, making diabetes the leading cause of new cases of blindness in adults aged 20 to 74. Based on published data, Alimera estimates that there are as many as 300,000 new cases of DME each year and 1 million people have DME. There are no ophthalmic drug therapies currently approved by the U.S. Food and Drug Administration for the treatments of DME.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatm
'/>"/>

SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
9. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/10/2014)... 2014 Fatigue, lack of safety ... number of accidents in the workplace, according to ... articles highlight safety issues that contribute to the ... occur on the job annually, according to the ... explore "preventable workplace accidents." , Safety Issue: "Extended ...
(Date:7/10/2014)... July 10, 2014 Thousands of ... in Copenhagen this July 13-17 to reveal the ... world closer to breakthroughs in dementia science. The ... largest conference of its kind. , As part ... as a catalyst for generating new knowledge about ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
Breaking Medicine News(10 mins):Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2
... the appointment of Terence M. O,Brien as its ... an in-depth national search for the position vacated ... in June. O,Brien will assume his new ... healthcare delivery system, which is comprised of a ...
... A system that can recognize human gestures could provide ... interact with computers. A related system for the able ... more realistic. The system is described in detail in ... Arts and Technology . , Manolya Kavakli of the ...
... you first notice a door handle, your brain has ... sees the handle, then it sends information to various ... out the details, such as color and the direction ... object is sent further along the various brain pathways, ...
... to outer space for help in their attempt to ... southern China. , Once the Three Gorges Dam is ... space to determine whether changing water conditions in Poyang ... the snails associated with the chronic disease that can ...
... option , , THURSDAY, Dec. 18 (HealthDay News) -- The ... Web site Thursday intended to make choosing a nursing ... The updated Nursing Home Compare site uses a five-star ... motels, to rank institutions nationwide. , "The old site ...
... Society has worked out new guidelines for the diagnosis ... Malignant melanoma is responsible for 90% of deaths from ... last 30 years and UV radiation is thought to ... , Claus Garbe of Tbingen University and his ...
Cached Medicine News:Health News:Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer 2Health News:Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer 3Health News:Gesture recognition 2Health News:Study indicates how we make proper movements 2Health News:Watching water from space could aid disease prevention in China 2Health News:Watching water from space could aid disease prevention in China 3Health News:Government Launches Nursing Home Rating System 2Health News:Government Launches Nursing Home Rating System 3
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed to ... Farnsworth D15 test is used to separate ... The L'Anthony Desaturated test is much more ... deficiency from Normal. Both of these ...
... as easy as 1-2-3: just three simple steps ... with rapid information before they leave your office. ... the appropriate therapy; no more follow-up appointments or ... A Test is a rapid immunochromatographic assay for ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: